| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Adenovirus causes epidemic keratoconjunctivitis and it has induced large epidemic every year. New types have appeared recently, and ocular manifestations have changed. Antiviral activity of stavudine was evaluated in several types in vitro. It was shown that stavudine had dose-dependent inhibitory effect on novel types 53, 54 and 56 similarly with type 4 and 64 of conventional types indicating that stavudine is effective against novel adenovirus types that are currently causing epidemics. From the clinical analysis of adenoviral conjunctivitis caused by type 54, it was shown that clinical score of younger cases was significantly more serious than that of adult cases, indicating age specific clinical characteristics leading to clinical insight.
|
